- Home
- EURK vs IFRX Comparison
EURK vs IFRX Comparison
Compare EURK & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EURK
- IFRX
- Stock Information
- Founded
- EURK 2023
- IFRX 2007
- Country
- EURK Hong Kong
- IFRX Germany
- Employees
- EURK N/A
- IFRX N/A
- Industry
- EURK
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- EURK
- IFRX Health Care
- Exchange
- EURK NYSE
- IFRX Nasdaq
- Market Cap
- EURK 80.0M
- IFRX 65.8M
- IPO Year
- EURK 2024
- IFRX 2017
- Fundamental
- Price
- EURK $10.38
- IFRX $0.80
- Analyst Decision
- EURK
- IFRX Strong Buy
- Analyst Count
- EURK 0
- IFRX 4
- Target Price
- EURK N/A
- IFRX $7.75
- AVG Volume (30 Days)
- EURK 38.0K
- IFRX 730.3K
- Earning Date
- EURK 01-01-0001
- IFRX 05-07-2025
- Dividend Yield
- EURK N/A
- IFRX N/A
- EPS Growth
- EURK N/A
- IFRX N/A
- EPS
- EURK N/A
- IFRX N/A
- Revenue
- EURK N/A
- IFRX $140,242.00
- Revenue This Year
- EURK N/A
- IFRX $3.36
- Revenue Next Year
- EURK N/A
- IFRX $100.60
- P/E Ratio
- EURK $61.54
- IFRX N/A
- Revenue Growth
- EURK N/A
- IFRX 30.90
- 52 Week Low
- EURK $10.03
- IFRX $0.71
- 52 Week High
- EURK $10.41
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- EURK N/A
- IFRX 32.20
- Support Level
- EURK N/A
- IFRX $0.71
- Resistance Level
- EURK N/A
- IFRX $0.89
- Average True Range (ATR)
- EURK 0.00
- IFRX 0.14
- MACD
- EURK 0.00
- IFRX -0.13
- Stochastic Oscillator
- EURK 0.00
- IFRX 7.57
About EURK EUREKA ACQUISITION CORP
Eureka Acquisition Corp is a newly incorporated blank check company.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.